Printer Friendly

Obagi Medical Products to Present at Two Investor Conferences in March.

LONG BEACH, Calif. -- Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today that Company management will present a corporate overview at the following two investor conferences:

* The 22nd Annual Roth OC Growth Stock Conference to be held at the Ritz Carlton Hotel in Dana Point, California. The presentation will take place at 11:30 a.m. (PST) on Wednesday, March 17, 2010.

* The Sidoti & Company, LLC 14th Annual Emerging Growth Institutional Investor Forum to be held at the Grand Hyatt Hotel in New York City. The presentation will take place at 7:00 a.m. (PST) on Wednesday, March 24, 2010.

A live webcast of each presentation will be available via the internet by visiting the Investor Relations section of the Company's web site at The archived presentation will be available on the web site for 30 days after each respective conference.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics[TM] technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm[R], 1988; Obagi-C[R] Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi[R] Professional-C (a line of highly stable vitamin C serums), 2005; Obagi[R] Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm[TM] eye treatment and Obagi CLENZIderm[R] M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm[R] M.D. Systems for normal to dry skin, June 2007; Obagi ELASTIderm[TM] Decolletage System, January 2008; the Obagi[R] Rosaclear[R] System for Rosacea in January 2009; and Refissa[TM] Tretinoin Emollient Cream, 0.05%, September 2009. Visit for more information.
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Conference news
Date:Mar 3, 2010
Previous Article:Research and Markets: Telecom Sector in New Zealand - Trends and Opportunities (2009-2013).
Next Article:MakeMusic's Monthly SmartMusic Subscription Report- February 2010.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters